Status:
COMPLETED
Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron
Lead Sponsor:
Bayer
Conditions:
Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Eligibility:
All Genders
18-50 years
Brief Summary
* The primary aim of this study is to evaluate the impact of titration, analgesics, and 12 month telephone follow-up period from the B.E.T.A nurse program upon adherence to treatment with Betaseron in...
Eligibility Criteria
Inclusion
- Have no cognitive impairment that may prevent patient from completing questionnaires, as assessed by examining physicians during screening
- Diagnosis of early (\<1 year since onset) RRMS, or a first clinical episode suggestive of demyelinating disease (not explained by other conditions) within the last 90 days prior to screening
- Presence of at least 2 typical MS lesions by brain MRI
- Kurtzke Expanded Disability Status Scale (EDSS) score of 0 - 4.0
- Willing to enroll into the MS Pathways support program and by doing so agree to be trained, and have follow-up phone calls, by a B.E.T.A. nurse
Exclusion
- Any disease other than multiple sclerosis that would better explain the patient's neurological signs and symptoms
- Complete transverse myelitis or simultaneous onset of optic neuritis
- Diagnosis of Primary progressive MS, secondary Progressive MS, relapsing progressive MS or a diagnosis of relapsing remitting MS for greater than 12 months
- Clinically significant heart disease such as uncontrolled cardiac dysrhythmias, uncontrolled angina pectoris, cardiomyopathy, or uncontrolled heart failure
- History of severe, uncontrolled, or untreated depression, attempted suicide or suicidal ideation
- Uncontrolled seizure disorder
- History or hypergammaglobulinemia
- Known hypersensitivity to IFNB-1b or other human proteins including albumin
- Known allergy to Gadolinium-DTPA documented prior to study entry
- Known general hypersensitivity to all analgesic / antiinflammatory agents (NSAIDs)
- Participation in any MS clinical study within the past six months
- Pre-treatment with any of the following substances prior to study enrollment within said time period:
- At any time: any IFN, glatiramer acetate (Copaxone), total lymphoid irradiation, anti-lymphocyte monoclonal antibody treatment (i.e. anti-CD4, anti-CD52 (alemtuzumab), anti-VLA4 (natalizumab), mitoxantrone, cyclophosphamide, azathioprine, IVIG, cyclosporine A, methotrexate, or any other immunomodulating or immunosuppressive agent including other recombinant or non-recombinant cytokines
- 3 months prior to study entry: any other treatment known to be used for putative or experimental MS treatment. Any presumed immunomodulating agent (e.g. statins) not described in this protocol
- History of alcohol or substance abuse (within the past 5 years)
- Inability or unwillingness to administer subcutaneous injections either by self or by caregiver
- Clinically significant hepatic, renal, or bone marrow dysfunction as defined by any of the following laboratory evaluations:
- Hepatic dysfunction: AST (SGOT) \> 3x the upper limit of normal or total bilirubin \> 2x upper limit of normal
- Renal dysfunction: creatinine \> 1.8 mg/dl
- Bone marrow dysfunction: Hb \< 8.5 g/dl, WBC \< 2.5x10\^9/L, or platelet count \< 125x10\^9/L
- Patients participating in the exploratory substudy should be excluded if they meet any of the following:
- Known history of chronic glaucoma, ocular hypertension, ischemic optic neuropathy, temporal arteritis, pseudopapilledema, retinitis pigmentosa, traumatic optic neuropathy, toxic optic neuropathy, pernicious anemia, or Leber's hereditary optic neuritis
Key Trial Info
Start Date :
May 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2009
Estimated Enrollment :
104 Patients enrolled
Trial Details
Trial ID
NCT00461396
Start Date
May 1 2007
End Date
November 1 2009
Last Update
April 8 2011
Active Locations (19)
Enter a location and click search to find clinical trials sorted by distance.
1
Many Locations, Alabama, United States
2
Many Locations, Arizona, United States
3
Many Locations, Delaware, United States
4
Many Locations, District of Columbia, United States